BRIDGEWATER, N.J. Nautilus Neurosciences has launched a new treatment for migraines, the drug maker said Tuesday.
Nautilus announced the launch of Cambia (diclofenac potassium), a water-soluble powder approved by the Food and Drug Administration in June 2009. Migraine affects more than 36 million people in the United States, three quarters of them women.
“The approval and subsequent commercialization of Cambia as a unique formulation of diclofenac offers an important treatment option for the millions of people who suffer from migraines,” University of California at Los Angeles neurology professor Alan Rapoport said. “With a simple, quick administration that can be used at any time during a migraine attack, Cambia offers rapid onset of pain relief with an established safety profile.”